Literature DB >> 19498017

Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies.

J A Cabrera-Gómez1, M Bonnan, A González-Quevedo, A Saiz-Hinarejos, R Marignier, S Olindo, F Graus, D Smadja, H Merle, L Thomas, A Gómez-García, P Cabre.   

Abstract

BACKGROUND: In Caucasian populations neuromyelitis optica (NMO-IgG) antibody has been detected in 27.1% / 78.2% of patients with relapsing-NMO (R-NMO). The prevalence reported for the disease in the Caribbean is 3.1/100,000 in the French West Indies (FWI) and 0.52 /100,000 in Cuba, but the NMO antibody status is unknown.
OBJECTIVE: To assess the NMO-IgG antibody status of Cuban/FWI RNMO patients, comparing with European cases tested at the same laboratories.
METHODS: Serum NMO-IgG antibodies were assayed in 48 R-NMO patients (Wingerchucks 1999 criteria): Cuba (24)/FWI (24), employing Lennon et aĺs method. We compared the demographic, clinical, disability and laboratory data between NMO-IgG +/- patients. All the data were reviewed and collected blinded to the NMO-IgG status.
RESULTS: Seropositivity of the NMO-IgG antibody demonstrated a lower rate in the Caribbean (33.3%), as compared with Caucasian patients from Spain/Italy (62.5%) and France (53.8%). Caribbean patients with NMO-IgG (+) displayed more attacks, more spinal attacks and a higher EDSS than NMO-IgG (-) cases, while brain and spinal cord MRI lesions were more frequent during remission, with more vertebral segments, more gray, white matter and holocord involvement.
CONCLUSIONS: NMO IgG positive antibodies in NMO patients had a lower rate in the Caribbean area - where the population has a predominant African ancestry - than in Caucasian Europeans, suggesting the influence of a possible ethnic factor in the pathogenesis of the disease, but they confer a worse course with more attacks, more disability and MRI lesions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19498017     DOI: 10.1177/1352458509104585

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  13 in total

1.  Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions.

Authors:  Yanqiang Wang; Lei Zhang; Bingjun Zhang; Yongqiang Dai; Zhuang Kang; Ciyong Lu; Wei Qiu; Xueqiang Hu; Zhengqi Lu
Journal:  J Neurol       Date:  2014-03-09       Impact factor: 4.849

Review 2.  Update on neuromyelitis optica: natural history and management.

Authors:  Panitha Jindahra; T Plant
Journal:  Eye Brain       Date:  2012-03-26

3.  Neuromyelitis optica and pregnancy.

Authors:  Yára Dadalti Fragoso; Tarso Adoni; Denis Bernardi Bichuetti; Joseph Bruno Bidin Brooks; Maria Lucia Brito Ferreira; Enedina Maria Lobato Oliveira; Celso Luis Silva Oliveira; Sonia Beatriz Felix Ribeiro; Alex Eduardo Silva; Fabio Siquineli
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849

4.  Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients.

Authors:  Gulsen Akman-Demir; Erdem Tüzün; Patrick Waters; Sema Içöz; Murat Kürtüncü; Sven Jarius; Zuhal Yapıcı; Melike Mutlu; Nilüfer Yeşilot; Angela Vincent; Mefkure Eraksoy
Journal:  J Neurol       Date:  2010-10-17       Impact factor: 4.849

5.  Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D.

Authors:  Maureen A Mealy; Audra Boscoe; Jaime Caro; Michael Levy
Journal:  Int J MS Care       Date:  2019 May-Jun

6.  Eye disorders in patients with multiple sclerosis: natural history and management.

Authors:  Jennifer Graves; Laura J Balcer
Journal:  Clin Ophthalmol       Date:  2010-12-06

7.  Neuromyelitis optica: an antibody-mediated disorder of the central nervous system.

Authors:  Jiwon Oh; Michael Levy
Journal:  Neurol Res Int       Date:  2012-01-29

8.  Plasma exchange in severe attacks of neuromyelitis optica.

Authors:  Mickael Bonnan; Philippe Cabre
Journal:  Mult Scler Int       Date:  2012-02-12

9.  Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study.

Authors:  Regina Maria Papais-Alvarenga; Claudia Cristina Ferreira Vasconcelos; Adriana Carra; Ibis Soto de Castillo; Sara Florentin; Fernando Hamuy Diaz de Bedoya; Raul Mandler; Luiza Campanella de Siervi; Maria Lúcia Vellutini Pimentel; Marina Papais Alvarenga; Marcos Papais Alvarenga; Anderson Kuntz Grzesiuk; Ana Beatriz Calmon Gama Pereira; Antonio Pereira Gomes Neto; Carolina Velasquez; Carlos Soublette; Cynthia Veronica Fleitas; Denise Sisteroli Diniz; Elizabeth Armas; Elizabeth Batista; Freda Hernandez; Fernanda Ferreira Chaves da Costa Pereira; Heloise Helena Siqueira; Hideraldo Cabeça; Jose Sanchez; Joseph Bruno Bidin Brooks; Marcus Vinicius Gonçalves; Maria Cristina Del Negro Barroso; Maria Elena Ravelo; Maria Carlota Castillo; Maria Lúcia Brito Ferreira; Maria Sheila Guimarães Rocha; Monica Koncke Fiuza Parolin; Omaira Molina; Patricia Beatriz Christino Marinho; Paulo Pereira Christo; Renata Brant de Souza; Silvio Pessanha Neto; Solange Maria das Graças Camargo; Suzana Costa Machado; Vanderson Carvalho Neri; Yara Dadalti Fragoso; Helcio Alvarenga; Luiz Claudio Santos Thuler
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

10.  Aquaporin-4 immuneglobulin g testing in 36 consecutive jamaican patients with inflammatory central nervous system demyelinating disease.

Authors:  Sherri Sandy; Sean J Pittock; Terence A R Seemungal; Amza Ali
Journal:  Neurol Int       Date:  2014-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.